Present-day trends in treatment of bacterial vaginosis
The most frequent infectious disease of the female reproductive system is bacterial vaginosis (BV). The increased interest in this nosology is explained by the clinical manifestation severity of the disease, rather than numerous data indicating the inextricable connection between BV and inflammatory...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-04-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2416 |
| _version_ | 1797841340447326208 |
|---|---|
| author | E. V. Lisovskaya E. G. Khilkevich |
| author_facet | E. V. Lisovskaya E. G. Khilkevich |
| author_sort | E. V. Lisovskaya |
| collection | DOAJ |
| description | The most frequent infectious disease of the female reproductive system is bacterial vaginosis (BV). The increased interest in this nosology is explained by the clinical manifestation severity of the disease, rather than numerous data indicating the inextricable connection between BV and inflammatory diseases of female genitourinary system and the complications of pregnancy and delivery. The bacterial biofilm formation, which is found in 90% of cases, have been shown to provide bacteria with protection against antimicrobial agents, representing the specificity of the BV pathogenesis, which militates against the effectiveness of the treatment. The official guidelines recommend to use metronidazole and clindamycin as the first-line therapy for BV in Russia and abroad. However, the present-day concept of BV therapy provides for a comprehensive two-stage treatment with a wide range of combination drugs to eradicate BV-associated microorganisms. Due to the lack of a systemic effect, the preference should be given to combination drugs designed for local therapy. Tergynan is one of the most popular drugs used for topical BV therapy, which demonstrated clinical efficacy and ease of use. Analogue of Tergynan, ornidazole + neomycin + prednisolone + econazole is a topical drug with antibacterial, antifungal and anti-inflammatory components, but has more modern antibacterial (ornidazole) and antifungal (econazole) components. The Russian studies showed convincing efficacy, safety and ease of use of a drug containing ornidazole + neomycin + prednisolone + econazole in BV therapy, which makes it possible to recommend it for practical use. |
| first_indexed | 2024-04-09T16:29:25Z |
| format | Article |
| id | doaj.art-2e9df1f0bac447afab71d44643acf9e1 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:29:25Z |
| publishDate | 2018-04-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-2e9df1f0bac447afab71d44643acf9e12023-04-23T06:57:08ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-04-010710611110.21518/2079-701X-2018-7-106-1112390Present-day trends in treatment of bacterial vaginosisE. V. Lisovskaya0E. G. Khilkevich1V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of RFV.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of RFThe most frequent infectious disease of the female reproductive system is bacterial vaginosis (BV). The increased interest in this nosology is explained by the clinical manifestation severity of the disease, rather than numerous data indicating the inextricable connection between BV and inflammatory diseases of female genitourinary system and the complications of pregnancy and delivery. The bacterial biofilm formation, which is found in 90% of cases, have been shown to provide bacteria with protection against antimicrobial agents, representing the specificity of the BV pathogenesis, which militates against the effectiveness of the treatment. The official guidelines recommend to use metronidazole and clindamycin as the first-line therapy for BV in Russia and abroad. However, the present-day concept of BV therapy provides for a comprehensive two-stage treatment with a wide range of combination drugs to eradicate BV-associated microorganisms. Due to the lack of a systemic effect, the preference should be given to combination drugs designed for local therapy. Tergynan is one of the most popular drugs used for topical BV therapy, which demonstrated clinical efficacy and ease of use. Analogue of Tergynan, ornidazole + neomycin + prednisolone + econazole is a topical drug with antibacterial, antifungal and anti-inflammatory components, but has more modern antibacterial (ornidazole) and antifungal (econazole) components. The Russian studies showed convincing efficacy, safety and ease of use of a drug containing ornidazole + neomycin + prednisolone + econazole in BV therapy, which makes it possible to recommend it for practical use.https://www.med-sovet.pro/jour/article/view/2416bacterial vaginosistherapytopical drugs |
| spellingShingle | E. V. Lisovskaya E. G. Khilkevich Present-day trends in treatment of bacterial vaginosis Медицинский совет bacterial vaginosis therapy topical drugs |
| title | Present-day trends in treatment of bacterial vaginosis |
| title_full | Present-day trends in treatment of bacterial vaginosis |
| title_fullStr | Present-day trends in treatment of bacterial vaginosis |
| title_full_unstemmed | Present-day trends in treatment of bacterial vaginosis |
| title_short | Present-day trends in treatment of bacterial vaginosis |
| title_sort | present day trends in treatment of bacterial vaginosis |
| topic | bacterial vaginosis therapy topical drugs |
| url | https://www.med-sovet.pro/jour/article/view/2416 |
| work_keys_str_mv | AT evlisovskaya presentdaytrendsintreatmentofbacterialvaginosis AT egkhilkevich presentdaytrendsintreatmentofbacterialvaginosis |